To Stop or Not to Stop? Approaches to Randomized Discontinuation Trials.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38319848.
- Also identified by DOI 10.1056/EVIDe2200127.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In health care, it is often clear when to start a treatment but not as obvious when to stop it. This uncertainty has particular relevance, for example, in the context of polypharmacy or management of a chronic disease. Both situations usually carry side effects resulting from pharmacointeractions or continued long-term use of medication, and they also impose a financial burden on patients and health care systems. In this issue of <i>NEJM Evidence</i>, Buhl et al.<sup>1</sup> evaluate the discontinuation of infliximab therapy in patients with Crohn's disease.